Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 1-Year Low at $142.14

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as $142.14 and last traded at $143.25, with a volume of 45496 shares changing hands. The stock had previously closed at $143.80.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ALNY shares. The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $230.00 to $173.00 in a report on Friday, February 16th. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 13th. Chardan Capital cut their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating on the stock in a report on Friday, February 16th. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday. Nine research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $216.12.

Alnylam Pharmaceuticals Trading Down 0.1 %

The firm has a market capitalization of $18.10 billion, a P/E ratio of -40.05 and a beta of 0.39. The business has a 50-day moving average of $150.36 and a 200 day moving average of $166.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. During the same period in the previous year, the firm earned ($1.68) EPS. The company's revenue was up 31.2% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company's stock worth $2,286,181,000 after purchasing an additional 287,064 shares during the period. Wellington Management Group LLP increased its holdings in shares of Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company's stock worth $1,139,074,000 after purchasing an additional 364,021 shares during the period. Capital International Investors increased its holdings in shares of Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company's stock worth $686,641,000 after purchasing an additional 488,814 shares during the period. Capital Research Global Investors increased its holdings in shares of Alnylam Pharmaceuticals by 5.3% in the fourth quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company's stock worth $560,880,000 after purchasing an additional 146,236 shares during the period. Finally, Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $390,438,000. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.